FDA panel says risk of opioid use in kids’ cough medicines outweighs benefits
A federal advisory committee declared nearly unanimously that the risks of using certain opioids in children’s cough medications outweighs the benefits.
ROCKVILLE, Md. — A federal advisory committee sent a strong message to the Food and Drug Administration on Monday, declaring nearly unanimously that the risks of using certain opioids in children’s cough medications outweighs the benefits.
“We have a disease with a very low risk profile, yet we’re looking at a drug that has a risk of death,” said Dr. Christy Turer, an assistant professor of pediatrics, clinical sciences, and medicine at the University of Texas Southwestern. “That, to me, seems very disproportionate.”
The recommendation by the
